AHA: Apixaban Beneficial for Patients With Subclinical A-Fib

Risk for stroke or systemic embolism lower with apixaban versus aspirin for patients with subclinical a-fib

Related Keywords

United States ,Stockholm ,Sweden ,Canada ,Philadelphia ,Pennsylvania ,American ,Emma Svennberg ,Jeffs Healey ,Karolinska University Hospital ,American Heart Association Scientific Sessions ,Medtronic ,Bristol Myers Squibb ,Mcmaster University ,Pfizer Alliance ,Healthday News ,New England Journal ,Bristol Myers Squibb Pfizer Alliance ,